WINTON GROUP Ltd Grows Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• WINTON GROUP Ltd boosted its stake in Regeneron by 219.2% in Q3, adding 2,966 shares to hold 4,319 shares worth about $2.43 million.
• Insiders have been net sellers, disposing of 5,274 shares worth $4.14 million over the past three months (including SVP Jason Pitofsky and Director Bonnie L. Bassler), and insiders now own 7.02% of the stock.
• Analysts show a consensus "Moderate Buy" with a $802.27 target (Barclays initiated at "Overweight" with $923), while Regeneron recently beat quarterly EPS/revenue estimates and raised its quarterly dividend to $0.94 ($3.76 annual).

WINTON GROUP Ltd boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 219.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,319 shares of the biopharmaceutical company's stock after acquiring an additional 2,966 shares during the period. WINTON GROUP Ltd's holdings in Regeneron Pharmaceuticals were worth $2,428,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $31,000. Caitlin John LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $34,000. Traub Capital Management LLC bought a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $38,000. Finally, E Fund Management Hong Kong Co. Ltd. boosted its stake in Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 35 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Jason Pitofsky sold 2,036 shares of the company's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares of the company's stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 5,274 shares of company stock worth $4,142,738 over the last three months. 7.02% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have issued reports on REGN shares. Barclays assumed coverage on Regeneron Pharmaceuticals in a research note on Friday, March 6th. They issued an "overweight" rating and a $923.00 price objective on the stock. Scotiabank increased their target price on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a "sector perform" rating in a research report on Monday, November 24th. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a "sector perform" rating in a report on Monday, March 2nd. Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an "equal weight" rating in a research note on Monday, February 2nd. Finally, Zacks Research lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $802.27.

Regeneron Pharmaceuticals Stock Down 1.2%

Shares of REGN opened at $772.03 on Wednesday. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The business has a fifty day moving average of $770.79 and a 200 day moving average of $692.02. The company has a market cap of $81.62 billion, a PE ratio of 18.58, a P/E/G ratio of 2.10 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm posted $12.07 earnings per share. The business's revenue for the quarter was up 2.5% on a year-over-year basis. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.